Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA
Despite increasing availability of alternative treatment options, patients with SLE in the USA increasingly rely on glucocorticoid-based therapy. Efforts to improve the use of antimalarials and steroid-sparing immunosuppressants are needed.
Authors
- Rozalina Grubina McCoy (ORCID: https://orcid.org/0000-0002-2289-3183)
- Gabriel Figueroa‐Parra (ORCID: https://orcid.org/0000-0002-6077-8899)
- Alí Duarte‐García (ORCID: https://orcid.org/0000-0003-1749-5719)
- Nilay D. Shah (ORCID: https://orcid.org/0000-0002-8597-3447)
- Kenneth J. Warrington (ORCID: https://orcid.org/0000-0001-7708-2487)
- Herbert C. Heien
- Cynthia S. Crowson (ORCID: https://orcid.org/0000-0001-5847-7475)
Institutions
- University of Maryland, Baltimore (US)
- Mayo Clinic (US)
- Universidad Autónoma de Nuevo León (MX)
- WinnMed (US)
- Optum (United States) (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Lupus Science & Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/lupus-2024-001317
- Citations
- 4
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- American Diabetes Association
- Yale University
- Patient-Centered Outcomes Research Institute
- Rheumatology Research Foundation
- National Institutes of Health
- National Institute on Aging
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences